Dr. Reddy's Allowed to Manufacture Semaglutide for Export by Delhi High Court
Dr. Reddy's has been permitted by the Delhi High Court to manufacture Semaglutide for export. The court upheld a prior order, allowing manufacturing and export to countries without Novo Nordisk's patent registration. The matter remains sub-judice.
This ruling has a significant impact on Dr. Reddy's ability to engage in the Semaglutide market for export, potentially opening new revenue streams, although the matter is still sub-judice.
The court's decision allows Dr. Reddy's to proceed with manufacturing and exporting Semaglutide, which is a positive development for the company's business.
Dr. Reddy's Laboratories Limited has clarified a news article published on March 10, 2026, titled “Delhi High Court allows Dr Reddy's to make Semaglutide for export”. The article pertains to an ongoing interim injunction proceeding between Dr. Reddy's and Novo Nordisk regarding Semaglutide containing products. The Division Bench of the Delhi High Court, in its judgment dated March 09, 2026, upheld a previous Single-Judge Bench's order. This order permits Dr. Reddy's to manufacture Semaglutide in India and export it to countries where Novo Nordisk does not hold a patent registration. The court refused to grant an interim injunction on Semaglutide containing products.
The company has further informed that the matter remains sub-judice and at this stage, there is no material event or information that requires disclosure under Regulation 30 of the SEBI Listing Regulations.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.